Mr. Hugin worked at Celgene for 19 years and helped oversee the expansion of Celgene from a U.S.-based company into a global company with operations across 50 countries.
“Bob is an industry leader with deep operational, financial and commercial experience that is relevant to Allergan’s business and strategy,” said Brent Saunders, Allergan chairman and CEO. “He has a strong track record of developing innovative therapies, delivering strong business results and creating shareholder value. I look forward to working with Bob and to Allergan benefitting from his expertise.”
More articles on pharmacy:
23andMe wants to become a drug company, has 13 drugs in its pipeline: 5 notes
J&J CEO on partnership with Apple: ‘We’re going to save lives’
Medicare would pay for CAR-T therapy under new proposal
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
